JP7664180B2 - リツキシマブ耐性キメラ抗原受容体およびその用途 - Google Patents

リツキシマブ耐性キメラ抗原受容体およびその用途 Download PDF

Info

Publication number
JP7664180B2
JP7664180B2 JP2021563352A JP2021563352A JP7664180B2 JP 7664180 B2 JP7664180 B2 JP 7664180B2 JP 2021563352 A JP2021563352 A JP 2021563352A JP 2021563352 A JP2021563352 A JP 2021563352A JP 7664180 B2 JP7664180 B2 JP 7664180B2
Authority
JP
Japan
Prior art keywords
cells
cell
car
vector
expressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021563352A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532996A (ja
JP2022532996A5 (https=
JPWO2020219848A5 (https=
Inventor
トーマス チャールズ パーテル
バーブラ ジョンソン サス
マーク ダブリュ レオナルド
Original Assignee
アロジーン セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70847489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7664180(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アロジーン セラピューティクス，インコーポレイテッド filed Critical アロジーン セラピューティクス，インコーポレイテッド
Publication of JP2022532996A publication Critical patent/JP2022532996A/ja
Publication of JP2022532996A5 publication Critical patent/JP2022532996A5/ja
Publication of JPWO2020219848A5 publication Critical patent/JPWO2020219848A5/ja
Priority to JP2025063227A priority Critical patent/JP2025109712A/ja
Application granted granted Critical
Publication of JP7664180B2 publication Critical patent/JP7664180B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021563352A 2019-04-26 2020-04-24 リツキシマブ耐性キメラ抗原受容体およびその用途 Active JP7664180B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025063227A JP2025109712A (ja) 2019-04-26 2025-04-07 リツキシマブ耐性キメラ抗原受容体およびその用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962839455P 2019-04-26 2019-04-26
US62/839,455 2019-04-26
US202063005041P 2020-04-03 2020-04-03
US63/005,041 2020-04-03
PCT/US2020/029775 WO2020219848A1 (en) 2019-04-26 2020-04-24 Rituximab-resistant chimeric antigen receptors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025063227A Division JP2025109712A (ja) 2019-04-26 2025-04-07 リツキシマブ耐性キメラ抗原受容体およびその用途

Publications (4)

Publication Number Publication Date
JP2022532996A JP2022532996A (ja) 2022-07-21
JP2022532996A5 JP2022532996A5 (https=) 2023-04-28
JPWO2020219848A5 JPWO2020219848A5 (https=) 2023-04-28
JP7664180B2 true JP7664180B2 (ja) 2025-04-17

Family

ID=70847489

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021563352A Active JP7664180B2 (ja) 2019-04-26 2020-04-24 リツキシマブ耐性キメラ抗原受容体およびその用途
JP2025063227A Pending JP2025109712A (ja) 2019-04-26 2025-04-07 リツキシマブ耐性キメラ抗原受容体およびその用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025063227A Pending JP2025109712A (ja) 2019-04-26 2025-04-07 リツキシマブ耐性キメラ抗原受容体およびその用途

Country Status (21)

Country Link
US (2) US11896617B2 (https=)
EP (2) EP4295851A3 (https=)
JP (2) JP7664180B2 (https=)
KR (1) KR20220004076A (https=)
CN (1) CN113728001B (https=)
AU (2) AU2020263495B2 (https=)
BR (1) BR112021021178A2 (https=)
CA (1) CA3134308A1 (https=)
CO (1) CO2021014121A2 (https=)
DK (1) DK3959235T5 (https=)
ES (1) ES2961314T3 (https=)
FI (1) FI3959235T3 (https=)
IL (1) IL287487A (https=)
MX (1) MX2021012820A (https=)
MY (1) MY204280A (https=)
PE (1) PE20212369A1 (https=)
PH (1) PH12021552415A1 (https=)
SA (1) SA521430654B1 (https=)
SG (1) SG11202111031RA (https=)
TW (1) TWI865517B (https=)
WO (1) WO2020219848A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211266A1 (es) * 2017-10-31 2021-07-19 Allogene Therapeutics Inc Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas
JP2023545071A (ja) * 2020-10-09 2023-10-26 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） Ｐｄ１キメラポリペプチドを含む方法および組成物
EP4271817A2 (en) 2020-12-30 2023-11-08 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
AU2023362748A1 (en) * 2022-10-20 2025-06-05 Microcrispr Pvt Ltd. Attenuation of cytokine release syndrome in immunotherapy
JP2025535441A (ja) * 2022-10-20 2025-10-24 マイクロ クリスパー プライベート リミテッド 免疫療法におけるサイトカイン放出症候群の軽減
AU2023362746A1 (en) * 2022-10-20 2025-06-05 Microcrispr Pvt Ltd. Attenuation of cytokine release syndrome in immunotherapy
AU2023362749A1 (en) * 2022-10-20 2025-06-05 Microcrispr Pvt Ltd. Attenuation of cytokine release syndrome in immunotherapy
JP2025535444A (ja) * 2022-10-20 2025-10-24 マイクロ クリスパー プライベート リミテッド 免疫療法におけるサイトカイン放出症候群の軽減
CN119700678A (zh) * 2024-12-19 2025-03-28 武汉大学 一种司妥昔纳米球的合成及其偶联car-t细胞的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520074A (ja) 2013-05-13 2016-07-11 セレクティスＣｅｌｌｅｃｔｉｓ Ｃｄ１９特異的キメラ抗原受容体およびその使用
US20170173124A1 (en) 2015-12-18 2017-06-22 Ucl Business Plc Treatment
JP2017532018A (ja) 2014-09-02 2017-11-02 ベリカム ファーマシューティカルズ， インコーポレイテッド ＭｙＤ８８およびＣＤ４０ポリペプチドによるキメラ抗原受容体の共刺激
WO2018178377A1 (en) 2017-03-31 2018-10-04 Cellectis Sa Universal anti-cd22 chimeric antigen receptor engineered immune cells
JP2019509738A (ja) 2016-03-11 2019-04-11 ブルーバード バイオ， インコーポレイテッド ゲノム編集された免疫エフェクター細胞

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US20030036654A1 (en) 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
EP1438075A4 (en) 2001-10-02 2006-04-19 Inst Clayton De La Rech METHOD AND COMPOSITIONS ASSOCIATED WITH LENTIVIRAL VECTORS WITH LIMITED EXPRESSION AND ITS APPLICATIONS
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
AU2012209103B2 (en) 2011-01-26 2015-12-03 Takeda Pharmaceutical Company Limited Methods and compositions for the synthesis of multimerizing agents
CN110200997A (zh) 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
KR102437522B1 (ko) * 2012-05-25 2022-08-26 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
EP4303232A3 (en) 2013-02-15 2024-04-17 The Regents of The University of California Chimeric antigen receptor and methods of use thereof
WO2014151960A2 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
WO2015017214A1 (en) 2013-07-29 2015-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
JP2017505819A (ja) 2014-02-04 2017-02-23 カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ Ｂ細胞悪性腫瘍及び他のがんの治療に有用な自己ｔ細胞を産生する方法、並びにその組成物
US10934346B2 (en) 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
GB201403972D0 (en) * 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
ES2791248T3 (es) * 2014-08-19 2020-11-03 Novartis Ag Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
ES2869972T3 (es) 2015-01-26 2021-10-26 Cellectis Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
GB201518792D0 (en) * 2015-10-23 2015-12-09 Univ Manchester Production of proteins
EP3443001B1 (en) * 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
GB201609597D0 (en) 2016-06-01 2016-07-13 Univ Sheffield Therapy
SG11201810640RA (en) * 2016-06-08 2018-12-28 Intrexon Corp Cd33 specific chimeric antigen receptors
KR102746901B1 (ko) * 2017-03-03 2024-12-26 옵시디안 테라퓨틱스, 인크. Cd19 조성물 및 면역요법을 위한 방법
EP3784785A4 (en) 2018-04-23 2022-02-16 Duke University DOWNREGULATION OF SNCA EXPRESSION BY TARGETED EDITING OF DNA METHYLATION
CA3110922A1 (en) * 2018-08-28 2020-03-05 Immunotech Biopharm Co., Ltd. Improved therapeutic t cell

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520074A (ja) 2013-05-13 2016-07-11 セレクティスＣｅｌｌｅｃｔｉｓ Ｃｄ１９特異的キメラ抗原受容体およびその使用
JP2017532018A (ja) 2014-09-02 2017-11-02 ベリカム ファーマシューティカルズ， インコーポレイテッド ＭｙＤ８８およびＣＤ４０ポリペプチドによるキメラ抗原受容体の共刺激
US20170173124A1 (en) 2015-12-18 2017-06-22 Ucl Business Plc Treatment
JP2019509738A (ja) 2016-03-11 2019-04-11 ブルーバード バイオ， インコーポレイテッド ゲノム編集された免疫エフェクター細胞
WO2018178377A1 (en) 2017-03-31 2018-10-04 Cellectis Sa Universal anti-cd22 chimeric antigen receptor engineered immune cells

Also Published As

Publication number Publication date
EP4295851A3 (en) 2024-02-14
EP3959235A1 (en) 2022-03-02
AU2020263495B2 (en) 2025-09-25
EP3959235B1 (en) 2023-07-26
CA3134308A1 (en) 2020-10-29
CO2021014121A2 (es) 2021-10-29
BR112021021178A2 (pt) 2022-03-15
JP2022532996A (ja) 2022-07-21
FI3959235T3 (fi) 2023-09-27
KR20220004076A (ko) 2022-01-11
MY204280A (en) 2024-08-21
JP2025109712A (ja) 2025-07-25
IL287487A (en) 2021-12-01
AU2025279733A1 (en) 2026-01-15
DK3959235T5 (da) 2024-08-05
US20240277763A1 (en) 2024-08-22
WO2020219848A1 (en) 2020-10-29
US12447178B2 (en) 2025-10-21
SG11202111031RA (en) 2021-11-29
CN113728001B (zh) 2025-09-09
US11896617B2 (en) 2024-02-13
PH12021552415A1 (en) 2022-07-11
TWI865517B (zh) 2024-12-11
US20200384026A1 (en) 2020-12-10
EP4295851A2 (en) 2023-12-27
CN113728001A (zh) 2021-11-30
TW202106704A (zh) 2021-02-16
DK3959235T3 (da) 2023-10-16
SA521430654B1 (ar) 2024-08-11
AU2020263495A1 (en) 2021-10-28
PE20212369A1 (es) 2021-12-21
ES2961314T3 (es) 2024-03-11
MX2021012820A (es) 2021-11-25

Similar Documents

Publication Publication Date Title
JP7702874B2 (ja) Ｄｌｌ３標的化キメラ抗原受容体および結合剤
JP7664180B2 (ja) リツキシマブ耐性キメラ抗原受容体およびその用途
US20250171731A1 (en) Methods of manufacturing allogeneic car t cells
RU2816370C2 (ru) Устойчивые к ритуксимабу химерные антигенные рецепторы и пути их применения
RU2828787C2 (ru) Способы получения аллогенных t-клеток с car
HK40105171A (en) Rituximab-resistant chimeric antigen receptors and uses thereof
TWI917318B (zh) 靶向ｄｌｌ３的嵌合抗原受體和結合劑
HK40071084A (en) Rituximab-resistant chimeric antigen receptors and uses thereof
HK40071084B (en) Rituximab-resistant chimeric antigen receptors and uses thereof
HK40065098B (zh) 抗利妥昔单抗嵌合抗原受体及其用途
JP2025539380A (ja) Ｃｌａｕｄｉｎ １８．２を標的とするキメラ抗原受容体および結合剤、ならびにそれらの使用
HK40065098A (en) Rituximab-resistant chimeric antigen receptors and uses thereof
KR20230142760A (ko) Car t 세포 의약품의 제형 및 프로세스
HK40063038B (zh) 靶向dll3的嵌合抗原受体和结合剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230420

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250407

R150 Certificate of patent or registration of utility model

Ref document number: 7664180

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157